Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

被引：203

作者：

Gonzales, Andrea J. ^{[1
]}

Hook, Kenneth E. ^{[1
]}

Althaus, Irene W. ^{[1
]}

Ellis, Paul A. ^{[1
]}

Trachet, Erin ^{[1
]}

Delaney, Amy M. ^{[1
]}

Harvey, Patricia J. ^{[1
]}

Ellis, Teresa A. ^{[1
]}

Amato, Danielle M. ^{[1
]}

Nelson, James M. ^{[1
]}

Fry, David W. ^{[1
]}

Zhu, Tong ^{[2
]}

Loi, Cho-Ming ^{[2
]}

Fakhoury, Stephen A. ^{[3
]}

Schlosser, Kevin M. ^{[3
]}

Sexton, Karen E. ^{[3
]}

Winters, R. Thomas ^{[3
]}

Reed, Jessica E. ^{[3
]}

Bridges, Alex J. ^{[3
]}

Lettiere, Daniel J. ^{[4
]}

Baker, Deborah A. ^{[4
]}

Yang, Jianxin ^{[4
]}

Lee, Helen T. ^{[3
]}

Tecle, Haile ^{[3
]}

Vincent, Patrick W. ^{[4
]}

机构：

[1] Pfizer Global Res & Dev, Canc Biol, Ann Arbor, MI USA

[2] Pfizer Global Res & Dev, Pharmacokinet & Drug Metab, Ann Arbor, MI USA

[3] Pfizer Global Res & Dev, Chem, Ann Arbor, MI USA

[4] Pfizer Global Res & Dev, Canc Biol, Groton, CT USA

来源：

MOLECULAR CANCER THERAPEUTICS | 2008年 / 7卷 / 07期

关键词：

D O I：

10.1158/1535-7163.MCT-07-2232

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Signaling through the erbB receptor family of tyrosine kinases contributes to the proliferation, differentiation, migration, and survival of a variety of cell types. Abnormalities in members of this receptor family have been shown to play a role in oncogenesis, thus making them attractive targets for anticancer treatments. PF-00299804 is a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor currently in phase I clinical trials. PF-00299804 is believed to irreversibly inhibit erbB tyrosine kinase activity through binding at the ATP site and covalent modification of nucleophilic cysteine residues in the catalytic domains of erbB family members. Oral administration of PF-00299804 causes significant antitumor activity, including marked tumor regressions in a variety of human tumor xenograft models that express and/or overexpress erbB family members or contain the double mutation (L858R/T790M) in erbB1 (EGFR) associated with resistance to gefitinib and erlotinib. Furthermore, PF-00299804 shows exceptional distribution to human tumor xenografts and excellent pharmacokinetic properties across species.

引用

页码：1880 / 1889

页数：10

共 48 条

[11] Mechanism of action of erbB tyrosine kinase inhibitors [J].

Fry, DW .

EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :131-139

[12] Specific, irreversible inactivation of the epidermal growth factor receptor and erbB2, by a new class of tyrosine kinase inhibitor [J].

Fry, DW ;

Bridges, AJ ;

Denny, WA ;

Doherty, A ;

Greis, KD ;

Hicks, JL ;

Hook, KE ;

Keller, PR ;

Leopold, WR ;

Loo, JA ;

McNamara, DJ ;

Nelson, JM ;

Sherwood, V ;

Smaill, JB ;

Trumpp-Kallmeyer, S ;

Dobrusin, EM .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :12022-12027

[13] G1 cell cycle arrest due to the inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein [J].

Gonzales, AJ ;

Fry, DW .

EXPERIMENTAL CELL RESEARCH, 2005, 303 (01) :56-67

[14] Timeline - The discovery of receptor tyrosine kinases: targets for cancer therapy [J].

Gschwind, A ;

Fischer, OM ;

Ullrich, A .

NATURE REVIEWS CANCER, 2004, 4 (05) :361-370

[15] Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models [J].

Higgins, B ;

Kolinsky, K ;

Smith, M ;

Beck, G ;

Rashed, M ;

Adames, V ;

Linn, M ;

Wheeldon, E ;

Gand, L ;

Birnboeck, H ;

Hoffmann, G .

ANTI-CANCER DRUGS, 2004, 15 (05) :503-512

[16] ERBB receptors and cancer: The complexity of targeted inhibitors [J].

Hynes, NE ;

Lane, HA .

NATURE REVIEWS CANCER, 2005, 5 (05) :341-354

[17] Epidermal growth factor receptor: mechanisms of activation and signalling [J].

Jorissen, RN ;

Walker, F ;

Pouliot, N ;

Garrett, TPJ ;

Ward, CW ;

Burgess, AW .

EXPERIMENTAL CELL RESEARCH, 2003, 284 (01) :31-53

[18] HER-2/neu is rate-limiting for ovarian cancer growth - Conditional depletion of HER-2/neu by ribozyme targeting [J].

Juhl, H ;

Downing, SG ;

Wellstein, A ;

Czubayko, F .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (47) :29482-29486

[19] Tyrosine kinase inhibitors.: 19.: 6-alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors [J].

Klutchko, SR ;

Zhou, HR ;

Winters, RT ;

Tran, TP ;

Bridges, AJ ;

Althaus, IW ;

Amato, DM ;

Elliott, WL ;

Ellis, PA ;

Meade, MA ;

Roberts, BJ ;

Fry, DW ;

Gonzales, AJ ;

Harvey, PJ ;

Nelson, JM ;

Sherwood, V ;

Han, HK ;

Pace, G ;

Smaill, JB ;

Denny, WA ;

Showalter, HDH .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (04) :1475-1485

[20] EGFR mutation and resistance of non-small-cell lung cancer to gefitinib [J].

Kobayashi, S ;

Boggon, TJ ;

Dayaram, T ;

Janne, PA ;

Kocher, O ;

Meyerson, M ;

Johnson, BE ;

Eck, MJ ;

Tenen, DG ;

Halmos, B .

NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (08) :786-792

← 1 2 3 4 5 →